Clinical trials: Anti-PD-L1 Antibody
Cholangiocarcinoma
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
This study is a prospective, observational study designed to analyze the safety, tolerability, and efficacy of first-line treatment using the combination of gemcitabine and cisplatin plus anti-PD-1/PD-L1 antibodies for patients…
- Trial name
- NCT07291063
- Testing
- Anti-PD-1/PD-L1 antibody, Gemcitabine and Cisplatin Chemotherapy
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital